---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-022598"
form_type: "8-K"
ticker: "BMEA"
cik: "0001840439"
company_name: "Biomea Fusion, Inc."
filed_at: "2022-11-07T23:59:59+00:00"
generated_at: "2026-06-22T05:54:14.993307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biomea Fusion Q3 net loss $22.9M, cash $133.8M; advances BMF-219 into KRAS solid tumors and T2D

## Summary
- Net loss $22.9M in Q3 2022 ($12.6M in Q3 2021); cash & investments $133.8M vs $175.7M year-end 2021.
- BMF-219 Phase I COVALENT-101 enrolling four liquid tumor cohorts; Cohort I at Dose Level 3, no DLTs; initial data H1 2023.
- COVALENT-102 (Phase I/Ib) initiated for KRAS-mutated solid tumors (NSCLC, CRC, PDAC) under FDA clearance Oct 2022.
- COVALENT-111 (Phase I/II) dosed first type 2 diabetes patient; healthy volunteer portion completed with no safety signals.
- Expect IND submissions for BMF-500 (FLT3 inhibitor) and BMF-219 in T2D in H1 2023 and year-end 2022, respectively.

## SEC filing metadata
- accession: 0000950170-22-022598
- form_type: 8-K
- ticker: BMEA
- cik: 0001840439
- company_name: Biomea Fusion, Inc.
- filed_at: 2022-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/0000950170-22-022598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/bmea-20221107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-022598
- JSON: https://secwatch.observer/filing/0000950170-22-022598.json
- Plain text: https://secwatch.observer/filing/0000950170-22-022598.txt

## Key facts
- Earnings Releases
  Biomea Fusion, Inc. reported the quarter ended September 30, 2022 results: net income net loss attributable to common stockholders of $22.9 million.
  - Period: the quarter ended September 30, 2022
  - Net income: net loss attributable to common stockholders of $22.9 million
  - Result: reported results
  source text: On November 7, 2022, Biomea Fusion, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840439/000095017022022598/0000950170-22-022598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.